MyofascialPainSyndrome:ATreatmentReview

Myofascial pain syndrome (MPS) is a common musculoskeletal condition characterized by pain originating from trigger points in skeletal muscles. Despite its prevalence, there is a lack of specific diagnostic criteria and limited high-quality evidence for treatment approaches. The condition can result from trauma, spine problems, repetitive strain, poor posture, or physical deconditioning. Addressing the underlying cause is considered the most effective strategy, but trigger points may persist and reactivate if root causes aren't properly treated.

This comprehensive review aimed to evaluate the current evidence for both pharmacological and non-pharmacological treatments for myofascial pain syndrome.

The researchers conducted an extensive literature search across multiple databases including PubMed, Ovid, and Google Scholar. They prioritized randomized controlled trials when available, followed by observational studies, and included systematic reviews. They examined treatments for myofascial pain and also extrapolated evidence from related musculoskeletal conditions like fibromyalgia and tension headaches when direct MPS evidence was limited. The review covered pharmacological treatments including analgesics, muscle relaxants, anticonvulsants, antidepressants, and newer agents, as well as non-pharmacological approaches like dry needling, manual therapy, ultrasound, electrical stimulation, and laser therapy.

For pharmacological treatments, the evidence was generally limited. NSAIDs showed promise based on their effectiveness in related musculoskeletal conditions, though no specific RCTs exist for MPS. A diclofenac patch demonstrated statistically significant benefits for trapezius muscle pain. Tizanidine showed significant pain reduction in an open-label study.

Topical lidocaine patches consistently showed statistically significant improvements in pain thresholds and general activity. Among newer treatments, tropisetron injections provided significant pain improvement, though research was limited to one group of authors. For non-pharmacological treatments, dry needling and trigger point injections emerged as the most established interventions with multiple supporting studies. Manual therapy techniques like myofascial release showed promise but lacked controlled studies proving long-term effectiveness.

TENS demonstrated pain reduction in several studies, though effects were primarily short-term. Ultrasound results were mixed, with some studies showing benefits while meta-analyses found poor quality evidence. Botulinum toxin A injections showed promise in several studies but results were inconsistent across trials.

This review reveals that while many treatments are commonly used for myofascial pain syndrome, the evidence base remains surprisingly weak. The heterogeneity of MPS presentations and varying diagnostic criteria across studies make it difficult to draw firm conclusions about treatment effectiveness. Clinicians should focus primarily on identifying and treating underlying causes of MPS. For established trigger points, dry needling and trigger point injections appear to have the strongest evidence base and should be considered first-line interventional treatments.

Topical treatments like lidocaine patches offer a non-systemic option with good supporting evidence. The limited evidence for most pharmacological treatments suggests they should be used cautiously and typically as adjuncts to other therapies. Manual therapies may be beneficial but need to be combined with other approaches for sustained benefit. More high-quality research with standardized diagnostic criteria and outcome measures is urgently needed to establish evidence-based treatment protocols for this common and often debilitating condition.